mTORC1, via S6K1, also improves the translation of c-MYC and, in turn, inhibits the transcription of miR-23a and miR-23b, which post-transcriptionally repress GLS (Gao et al., 2009)
For us as clinicians, the 2035 projections map directly onto the chronic disease burden we'll be managingmore diabetes, more cardiovascular disease, more musculoskeletal disease, more Alzheimer's, and higher costs across the board
The tirzepatide they offer is a compounded version, which means it is produced by a compounding pharmacy rather than manufactured by the original drug maker
Long-term use of semaglutide may even lower the risk of major cardiovascular events like heart attacks, particularly in patients with type 2 diabetes